MedTrace Logo

A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder

NCT06673368 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2026-01-15

No results posted yet for this study

Summary

A combination therapy of NRCT-101 with NRCT-202 is being developed for patients with ADHD.

Conditions

  • ADHD

Interventions

DRUG

NRCT-101SR, NRCT-202XR

NRCT-101SR in combination with NRCT-202XR or NRCT-202XR alone

Sponsors & Collaborators

  • Neurocentria, Inc.

    lead INDUSTRY

Principal Investigators

  • Guy Bar-Klein, PhD · Neurocentria, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
13 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-25
Primary Completion
2025-07-15
Completion
2025-07-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06673368 on ClinicalTrials.gov